Richard Marshak Biography and Net Worth

Dr. Richard Marshak was appointed Chief Commercial Officer in January 2025. Previously he served as Senior Vice President, Corporate Development, Strategy, and Marketing at TriSalus since June 2022.

Previously, Dr. Marshak was Managing Principal of LF Consulting, a consulting firm for biotechnology companies, from June 2013 to June 2022. Dr. Marshak also co-founded Nephraegis Therapeutics, a biotechnology company, in September 2018 and served as its Chief Business Officer. Previously, Dr. Marshak served as the Chief Executive Officer of Mount Tam Biotechnologies from May 2016 to October 2019. Prior to these roles, Dr. Marshak held several progressive leadership roles in Abbott Laboratories, a multinational medical devices and health care company, from 1999 to 2013, culminating as the Head of Global Strategic Pricing. Dr. Marshak has served on the board of directors of Nephraegis Therapeutics since August 2018 and previously served on the board of Mount Tam Biotechnologies from May 2016 to October 2019.

Dr. Marshak received his B.A. in Psychology and VMD in Veterinary Medicine from the University of Pennsylvania, and his MBA from the University of Chicago.

What is Richard Marshak's net worth?: The estimated net worth of Richard Marshak is at least $463.67 thousand as of March 16th, 2026. Marshak owns 110,397 shares of TriSalus Life Sciences stock worth more than $463,667 as of June 22nd. This net worth estimate does not reflect any other assets that Marshak may own. Learn More about Richard Marshak's net worth.
How do I contact Richard Marshak?: The corporate mailing address for Marshak and other TriSalus Life Sciences executives is 6272 West 91st Avenue, Westminster, CO 80031, United States. TriSalus Life Sciences can also be reached via phone at 888-321-5212 and via email at [email protected]. Learn More on Richard Marshak's contact information.
Has Richard Marshak been buying or selling shares of TriSalus Life Sciences?: Richard Marshak has not been actively trading shares of TriSalus Life Sciences during the last quarter. Most recently, Richard Marshak sold 419 shares of the business's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $4.12, for a transaction totalling $1,726.28. Following the completion of the sale, the insider now directly owns 110,397 shares of the company's stock, valued at $454,835.64. Learn More on Richard Marshak's trading history.
Who are TriSalus Life Sciences' active insiders?: TriSalus Life Sciences' insider roster includes Bryan Cox (Chief of Research), Gary Gordon (Director), Richard Marshak (Insider), George Martin (Director), Michael Stansky (Director), Mary Szela (Chief Executive Officer, President and Director), and Mats Wahlstrom (Director). Learn More on TriSalus Life Sciences' active insiders.
Are insiders buying or selling shares of TriSalus Life Sciences?: During the last twelve months, TriSalus Life Sciences insiders bought shares 5 times. They purchased a total of 719,682 shares worth more than $1,804,176.38. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 30,150 shares worth more than $119,849.35. The most recent insider tranaction occured on May, 15th when Director Mats Wahlstrom bought 60,000 shares worth more than $151,800.00. Insiders at TriSalus Life Sciences own 16.3% of the company. Learn More about insider trades at TriSalus Life Sciences.
Information on this page was last updated on 5/15/2026.

Richard Marshak Insider Trading History at TriSalus Life Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/16/2026	Sell	419	$4.12	$1,726.28	110,397
3/12/2026	Sell	1,589	$4.09	$6,499.01	110,816
3/11/2026	Sell	1,449	$4.13	$5,984.37	112,405
5/19/2025	Sell	6,597	$5.18	$34,172.46	69,101

Richard Marshak Buying and Selling Activity at TriSalus Life Sciences

TriSalus Life Sciences Company Overview

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Today's Range

Now: $4.20

$3.95

$4.23

50 Day Range

MA: $3.87

$2.52

$4.65

2 Week Range

Now: $4.20

$2.20

$7.95

Volume

229,068 shs

Average Volume

296,130 shs

Market Capitalization

$257.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49